Research has shown that migraines are linked to inflammation.
A clinical trial examined Coenzyme Q10โs (CoQ10โs) effects on episodic migraines in women, finding significant reductions in migraine frequency, duration, severity. CoQ10 also reduced the levels of TNF-ษ and CGRP, a peptide linked to migraines that promotes inflammation and pain signaling.
A meta-analysis of five studies concluded that CoQ10 supplementation is more effective than a placebo in reducing migraine occurrence and duration in both children and adults.
โThe results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days/month.โ (Zeng et al., 2018)
These findings were corroborated in a subsequent meta-analysis of six clinical trials that showed CoQ supplemented as a preventative measure was effective for reducing the duration and frequency of migraines.